Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
16 drugs in development
By Therapeutic Area
top 6
R&D Momentum
90/100
Pipeline Velocity
70/100
Trial Completion Rate
66/100
Pipeline Concentration
14/100
Pipeline Freshness
68/100
Strategic Signals
Activity
Last 14 days
Symptom Monitoring Using Patient-Reported Outcomes to Optimize Medication Use
Low Dose Naltrexone in the Treatment of Central Neuropathic Pain After Traumatic Spinal Cord Injury: A Pilot Study
Probiotic-induced Normalization of Innate Inflammation in Youth Newly Diagnosed With Type 1 Diabetes
PREVENTION OF RECURRENCE OF CLOSTRIDIOIDES DIFFICILE COLITIS WITH URSODEOXYCHOLIC ACID (UCDA) AS A SUPPLEMENT TO STANDARD THERAPY
Probiotics for Inflammation in Pediatric Chronic Pain
Impact of Lp299v on Vascular Function in Patients With PASC
Improving In-hospital and Post-discharge Patient Education for Mild Traumatic Brain Injury
Understanding Breast Cancer Risk and Screening in Individuals on Hormone Therapy Through a Pilot Breast Cancer Screening Program
Impact of Lp299v on Vascular Aging in Healthy Adults
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)